Final Court Approval Clears Path for Company Shutdown
A federal judge has approved the criminal sentence for Purdue Pharma, marking a critical step toward dissolving the company and implementing a sweeping opioid settlement tied to one of the deadliest public health crises in U.S. history.
The ruling allows the settlement plan to move forward, which will see the company shut down and replaced by a new public-benefit entity focused on addressing opioid addiction and prevention.
Company Admits Misleading Regulators
As part of the case, Purdue acknowledged it failed to maintain an effective system to prevent its prescription opioid OxyContin from being diverted into illegal markets.
Despite assurances to the U.S. Drug Enforcement Administration, the company admitted its safeguards were inadequate.
It also conceded to controversial marketing practices, including incentivizing doctors to prescribe opioids and using data tools to push higher prescription rates.
Billions in Penalties — But No Individual Charges
The settlement includes $8.3 billion in penalties, though the federal government agreed to collect only a portion as part of a broader legal agreement resolving thousands of lawsuits.
Notably, no individuals — including members of the Sackler family — faced criminal charges, a point that has drawn criticism from victims and advocacy groups.
Victims Speak Out: “We Still Deserve Justice”
During the hearing, emotional testimonies highlighted the human cost of the opioid epidemic, which has been linked to over 900,000 deaths in the U.S. since 1999.
Many victims and families argued the settlement falls short of delivering justice.
One mother who lost her son to overdose said she may not receive compensation due to missing medical records, adding that financial payouts alone cannot address the harm caused.
Others, however, supported the agreement, saying it offers a path toward closure and recovery.
Sackler Family to Pay Up to $7 Billion
Under the deal, the Sackler family will contribute up to $7 billion over 15 years, with most funds directed toward combating opioid addiction through public programs.
The agreement also protects family members from future opioid-related lawsuits tied to the settlement.
What Happens Next
Once finalized, Purdue Pharma will cease operations and transition into a new entity called Knoa Pharma, designed to serve public health interests rather than profit motives.
Compensation for individual victims is expected to range between $8,000 and $16,000, while the majority of funds will go toward national and local efforts to address the opioid crisis.